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1. Introduction 
It is now widely acknowledged that, like other cancers, acute lymphoblastic leukaemia is 
caused by the acquisition of mutations in somatic cells. The first hit in childhood ALL has 
been documented to occur in most (if not all) cases before birth (Golub, 2007). The 
progress in genomics technology holds the promise of making the complete 
characterization of the ‘cancer genome’ possible by a systematic search for 
submicroscopical mutations. 
Molecular studies on recurrent chromosomal translocations in ALL have indicated that, 
beside the constitutive activation of tyrosine kinases, the aberrant expression of 
transcription factors plays a central role in the pathobiology of lymphoid leukaemia. This 
aberrant expression leads to abnormal proliferation and differentiation arrest of lymphoid 
progenitors (O'Neil & Look, 2007). In some cases, recurrent chromosomal translocations 
generate fusion transcription factors with new functions, enabling them to target genes 
other than those recognized by the endogenous factors. 
In the past few years, the PAX5 gene has been demonstrated to be a recurrent target of 
genetic alterations in B-lineage ALL, both in adult and paediatric patients (Mullighan et al., 
2007). The role of these aberrancies in human leukemogenesis is still, however, poorly 
understood (Cobaleda et al., 2007a).  
This chapter will review the role of PAX5 gene involvement in B-lineage ALL to outline the 
biological and functional effects of different genetic aberrations affecting this new master 
gene in leukaemia. Moreover, we will address whether PAX5 alterations are driver or 
passenger lesions and finally what their potential prognostic impact can be.  
2. Role of the PAX5 transcription factor in normal B-cell precursor 
development 
The PAX5 gene, located on 9p13, belongs to the paired box (PAX) gene family of 
transcription factors, essential for B lymphoid cell commitment (Cobaleda et al., 2007a). 
Nine mammalian PAX transcription factors have been described, but PAX5 is the only PAX 
protein expressed in the haematopoietic system. In addition, PAX5 is expressed in the 
nervous system at the midbrain–hindbrain boundary and in adult testes.  
In B-cells, PAX5 fulfils a unique function by controlling the identity of B lymphocytes 
throughout B-cell development, from the pro-B to the mature B-cell stage. It functions both 
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as a transcriptional activator and as a repressor on different target genes, which are involved 
in lineage development (Busslinger, 2004; Matthias & Rolink, 2005).  
2.1 B-cell development 
Haematopoiesis is an ideal system for investigating the developmental relationships 
between cells of an organ system. All lineages can be reconstituted from a  single bone 
marrow-derived haematopoietic stem cell (HSC) (Ceredig et al., 2009). According to the 
classical “tree model” by Weissman, (Akashi et al., 2000; Manz et al., 2002) the 
haematopoietic system constantly generates a large number of specialized cell types from 
pluripotent haematopoietic stem cells (PHSCs), which have a self-renewal potential and give 
rise to different progenitors with a more restricted differentiation capacity (Busslinger, 2004; 
Matthias & Rolink, 2005).  
One of the earliest differentiated precursors is the multipotential progenitor (MPP), which is 
at the junction between the myeloid and lymphoid lineages. MPPs can differentiate into 
common myeloid progenitors (CMPs), common lymphoid progenitors (CLPs) or, as recently 
identified, early lymphoid progenitors (ELPs) (Matthias & Rolink, 2005). 
It is generally thought that CLPs have the potential to develop into lymphoid cells (B cells, T 
cells and NK cells), while the CMPs differentiate either 1) into granulocyte-monocyte 
progenitors (GMPs), (which subsequently produce mature granulocytes (neutrophils, 
basophils and eosinophils) and monocyte/macrophages,) or 2) into megakaryocyte-
erythrocyte progenitors (MEPs), which give rise to platelets and red erythrocytes (Akashi et 
al., 2000; Manz et al., 2002).  
However, the idea that CLPs have exclusively lymphoid but not myeloid potential has been 
questioned by several studies (Akashi et al., 2000; Adolfsson et al., 2005; Balciunaite et al., 
2005; Benz & Bleul, 2005). It has been suggested that immune-cell progenitors have both 
lymphoid and myeloid potential and a “circular model” has been proposed accordingly 
(Ceredig et al., 2009). These cells have been called early progenitors with lymphoid and 
myeloid potential (EPLMs), and they express B220, cKit (also known as CD117), IL-7 
receptor ┙-chain (IL-7r┙; also known as CD127), FLT3 (FmS-related tyrosine kinase 3, also 
known as CD135 and FlK2) and CD93, but do not express CD19 or NK1.1.  
Indeed, CD19 expression is completely controlled by PAX5, whose expression starts later in 
precursor B-cells. Research on the specific role of the PAX5 gene in haematopoietic 
development has demonstrated its requirement exclusively in B-cell development. A knock 
out mouse model has shown a complete block in B-cell differentiation, which is immediately 
downstream of the block that is seen in the absence of E2A or EBF (Nutt et al., 1999). 
Remarkably, PAX5-/- pre-BI cells have extraordinary developmental plasticity showing 
haematopoietic stem cell features such as multipotency and a self renewing capacity (Rolink 
et al., 2002a). In fact, it has been reported that EPLMs resemble PAX5-/- pro-B cells, since 
they can both differentiate in vitro into myeloid cells (macrophages and dendritic cells), NK 
cells and T cells (Balciunaite et al., 2005).  
The plasticity of EPLMs is greater than that of PAX5-/- pro-B cells because EPLMs can 
express PAX5 and thereby generate B-cells. It is possible that EPLMs are a mixture of 
committed progenitors and their fate is directed by signals and growth factors (Ceredig et 
al., 2009).  
Overall, these features support the key role of PAX5 in B-cell commitment and 
differentiation. Further details on its function will be discussed in paragraph 2.2.3. 
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Fig. 1. B-cell development. HSC, haematopoietic stem cell; MPP, multipotential progenitor; ELP, 
early lymphoid progenitor; CLP, common lymphoid progenitor; CMP, common myeloid progenitor; 
LSK, Lin- Scahi cKithi; ETP, early T progenitor. 
Schematically, B-cell development initiates in progenitors when they start expressing the 
recombination-activating gene 1 (Rag1) and Rag2 and the process of rearrangement at the 
immunoglobulin heavy chain (IgH) locus occurs. Indeed, the stages in primary B-cell 
development are defined by the sequential rearrangement and expression of heavy- and light-
chain immunoglobulin genes. Intermediate differentiation stages have been distinguished on 
the basis of the expression of other cell-surface proteins, together with direct DNA analysis of 
the state of the immunoglobulin gene loci (Janeway et al., 2001). More specifically, expression 
of the B-cell marker B220 by a subset of progenitors, known as pro-B cells, coincides with their 
entry into the B-cell differentiation pathway. Subsequently, CD19 is expressed and the IgH 
diversity (DH)-to-joining (JH) gene-segment rearrangement is completed, identifying pre-BI 
cells. The IgH locus then continues to rearrange its variable (V)-region gene segments until 
productive VH–DJH alleles are generated in large pre-BII cells. These cells cease to express 
Rag1 and Rag2, and they display the product of the rearranged IgH gene at the cell surface. 
There, they assemble with the surrogate immunoglobulin light chains (IgLs), VpreB and 5, 
together with the signalling molecules Ig┙ (which is encoded by the MB-1 gene) and Ig┚ 
(which is encoded by the B29 gene) to form a pre-B-cell receptor (pre-BCR). The expression of 
the pre-BCR is a crucial check-point in early B-cell development, and its signalling stimulates a 
proliferative clonal expansion of large pre-BII cells, which is followed by the re-expression of 
RAGs and rearrangement at the IgL locus in small pre-BII cells.  
Once an immature B cell expresses IgM on its surface (sIgM), its fate is guided by the nature 
of the signals it receives through its antigen receptor. Binding to self molecules in the bone 
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marrow can lead to the death or inactivation of immature B cells; otherwise they leave the 
bone marrow, enter the periphery and reach the spleen (Janeway et al., 2001). There they 
further differentiate through three transitional stages T1, T2 and T3, on the basis of the 
expression of various cell-surface markers, their short half-life (2–4 days) and their 
sensitivity to apoptosis induced by antibodies specific for IgM. Indeed transitional B cells 
can be negatively selected in the periphery. The tumour-necrosis-factor family member B-
cell-activating factor (BAFF; also known as BLYS) and its receptor play a crucial role in 
regulating the transition of immature B cells into mature B cells (Rolink & Melchers, 2002b; 
Rolink et al., 2002c). Transitional, follicular and even memory B cells can give rise to 
marginal-zone B cells (responsible for antibody response to blood pathogens) and/or be 
recruited into this compartment. In mice, most mature B cells are follicular B cells. These 
cells are mainly responsible for generating humoral immune responses to protein antigens. 
With the help of T cells, they form germinal centres. Germinal-centre B cells proliferate 
rapidly, undergo somatic hypermutation of their immunoglobulin variable gene segments 
and undergo isotype-switch recombination of immunoglobulin genes. Subsequently, 
germinal centres slowly vanish, and memory B cells and effector plasma cells are generated 
(Matthias & Rolink, 2005).  
2.1.1 Comparison between mouse and human B-cell development 
Most of our understanding of the initiation and regulation of Ig gene rearrangements in 
precursor B-cell differentiation comes from studies on mouse models. Genome-wide gene 
expression profiling has been performed in human precursor B-cells, contributing 
enormously to the understanding of lymphocyte differentiation. Therefore, Van Dongen and 
colleagues (van Zelm et al., 2005) purified cells in the five main stages of human precursor 
B-cell differentiation, pro-B, pre-BI, pre-BII large and small, and immature B-cells. In 
correspondence with each stage, the authors characterized the IGH and IGK/IGL 
rearrangements independently from each other and independently from the selection 
processes. Altogether they have deepened the knowledge about the different stages of 
human B-cell development, which seems to follow mechanisms similar to that of mice.  
This confirms the previous studies reviewed by Ghia (Ghia et al., 1998), in which they 
concluded that the main mechanisms of selection and the key events during B 
lymphopoiesis appear to be strikingly similar in murine and human bone marrow.  
There are some differences in surface marker expression (e.g. the absence of CD10 and CD34 
in mouse pre-BI cells and the absence of CD25 in human pre-BI cells) as well as different 
growth requirements. Human pre-BI cells are mainly unresponsive to IL-7; they can be 
grown only 3-4 weeks in vitro in presence of IL-7 and do not show a proliferative expansion 
comparable to mouse cells (Ghia et al., 1998).  
2.1.2 Transcription factors in B-cell precursor development  
The comprehension of the different stages of B-cell development is based on results from 
multiple levels of analysis including immunophenotype, status of immunoglobulin gene 
rearrangement, in vitro or in vivo cell differentiation properties (Matthias & Rolink, 2005) as 
well as gene-targeting studies of many regulatory molecules in mice. By these studies, B 
lymphopoiesis has emerged as one of the leading models for research on lineage 
specification (induction of a lineage-specific gene-expression program) and commitment 
(repression of alternative gene expression programs).  
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Transcription factors play a central role in this process. B-cell development, maturation and 
function are coordinated by a ‘battery’ of transcription factors and signal-transduction 
molecules that regulate the sequential execution of the different steps (Matthias & Rolink, 
2005; Nutt & Kee, 2007). 
The generation of lymphoid progenitors depends on signalling through the c-Kit, FLT3 and 
IL-7 receptors; in their absence, early B cell progenitors in the bone marrow are severely 
affected (Nutt & Kee, 2007).  
In addition, developmental control of early B lymphopoiesis is exerted by a regulatory 
network of key transcription factors that include PU.1 (an Ets-family member), Ikaros, 
Bcl11a (a zinc finger transcription factor), E2A (a helixloop-helix protein), EBF (early B-cell 
factor) and PAX5 (Fuxa & Skok, 2007).  
In particular, three transcription factors have been found to be essential for the 
differentiation of CLPs into specified pro-B cells: transcription factor E2A, early B-cell factor 
(EBF; also known as OLF1) and paired box protein 5 (PAX5; also known as BSAP). Absence 
of any one of these factors leads to an early block in B-cell development at the pro-B-cell or 
pre-B-cell stage. These three factors seem to work in collaboration, and together, they form a 
master control switch for engaging B-cell differentiation (Matthias & Rolink, 2005).  E2A and 
EBF are considered primary B-cell fate determinants and co-ordinately activate the 
expression of B-cell specific genes (e.g. both can initiate the remodelling of MB-1 promoter 
chromatin) (Fuxa & Skok, 2007). In the absence of E2A or EBF, B-cell development was 
blocked at early progenitor stages of development, however, EBF can activate the B-cell 
lineage program in absence of E2A or PU.1. Conversely, in the absence of EBF, B-cell 
development was not rescued by enforced expression of PAX5 (Hagman & Lukin, 2006).  
The ability of EBF to mediate activation of the B-cell program suggests that it has the 
properties of a ‘pioneer’ factor (i.e. a protein capable of initiating the activation of 
transcriptional quiescent genes) (Hagman & Lukin, 2005).  
However, the mere activation of the B lymphocyte transcription program is not sufficient to 
commit B cell progenitors to the B lymphoid lineage in the absence of the paired domain 
protein PAX5 (Fuxa & Skok, 2007). 
2.2 PAX5, the sentinel of B cells: identity and function 
The PAX5 gene is a member of the paired box (PAX) gene family of transcription factors and 
it is essential for B lymphoid lineage commitment (Morrison et al., 1998; Nutt et al., 1999; 
Souabni et al., 2002; Cotta et al., 2003) since it controls the identity of B lymphocytes 
throughout B-cell development from the pro-B to the mature B-cell stage (Busslinger, 2004; 
Matthias & Rolink, 2005).   
This factor has been implicated in the direct transcriptional regulation of several B-cell-
specific genes, such as those encoding CD19, Igα and BLNK/SLP-65 (Matthias & Rolink, 
2005).  
2.2.1 Cloning of PAX5 
PAX5 or the B-cell specific activator protein (BSAP) was independently discovered as a 
DNA-binding protein with the same DNA sequence specificity as the sea urchin 
transcription factor TSAP. Biochemical purification and cDNA cloning showed that BSAP is 
encoded by the PAX5 gene and is expressed in B lymphocytes, the developing CNS, and 
adult testes (Cobaleda et al., 2007a).  
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The human PAX5 gene is located on chromosome 9p13, is organized in 10 exons and 
encodes for a transcript of 8536 bp, giving rise to a coding sequence of 1176 bp, which in 
turn gives rise to a protein of 391 aa, a protein completely homologous to the Mus musculus 
PAX5 gene. Indeed, PAX5 retains a high degree of homology between humans and mice 
(Ghia et al., 1998).  
2.2.2 PAX5 protein structure 
PAX5 is a homeodomain protein, which is a member of a class of transcription factors that 
contains a DNA-binding domain with homology to Drosophila melanogaster homeodomain 
regulatory proteins. This DNA-binding domain contains a helix–turn–helix motif, which 
binds to a distinct half-site of the PAX5 recognition sequence in adjacent major grooves of 
the DNA helix (Cobaleda et al., 2007a).  
The defining feature of the PAX protein family is the conserved ‘paired’ domain, which 
functions as a bipartite DNA-binding region consisting of an N- and a C-terminal domain. 
The bipartite nature of the paired domain is responsible for its degenerate consensus 
recognition sequence, as each half-site independently contributes to the overall affinity of a 
given binding site (Czerny, 1995).  
The transcriptional activity of PAX5, which is responsible for regulating its target genes, is 
determined by the interaction of distinct partner proteins with the central and C-terminal 
protein interaction motifs of PAX5. The partial homeodomain of PAX5 associates with the 
TATA-binding protein of the basal transcription machinery, while a C-terminal 
transactivation domain regulates gene transcription most likely by interacting with histone 
acetyltransferases (HAT), such as the co-activator CBP or SAGA complex.  
In parallel, PAX5 acts as a repressor, and not as a transcriptional activator, through the 
binding of its conserved octapeptide motif to co-repressors of the Groucho protein family, 
which are part of a larger histone deacetylase (HDAC) complex (Cobaleda et al., 2007a).  
 
 
Fig. 2. PAX5 structure, showing functional domains and corresponding exons. DBD, DNA-
binding paired domain; OP, conserved octapepetide; HD, partial homeodomain; TAD, 
transactivation domain; ID, inhibitory domain. 
2.2.3 PAX5 is essential in B-cell development  
PAX5 is a transcription factor and localizes in the nucleus. In the haematopoietic system it is 
expressed exclusively in the B-cell compartment, where it is essential for the development of 
the specific lineage (Matthias & Rolink, 2005; Cobaleda et al., 2007a). 
The PAX5 knock out mouse model leads to a complete block in B-cell differentiation, 
immediately downstream of the block that is seen in the absence of E2A or EBF (their 
Exon 1 2 3 4 5 6 7 8 9 10 
5’ UTR 
DBD OP HD TAD ID
3’ UTR 
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expression is normal in PAX5–/– B cells) (Nutt et al., 1999). The rearrangement at the IgH 
locus has already been initiated (Matthias & Rolink, 2005); although DJ gene segments are 
rearranged normally in these cells, rearrangement of VH gene segments is severely 
impaired. PAX5 is required not only for rearrangement of VH gene segments and for 
expression of genes that are required for progression to the pre-B-cell stage but also for 
commitment to and maintenance of the B-cell differentiation pathway.  
Both in vitro and in vivo studies have demonstrated that, in the absence of PAX5, pre-BI cells 
show an extraordinary degree of plasticity demonstrating multipotency and a self renewing 
capacity. After stimulation with the appropriate cytokines, they can in fact differentiate in 
vitro into macrophages, osteoclasts, DCs, granulocytes or NK cells. In vivo, however, they 
develop into all the lineages, even into T cells, and erythrocytes (Rolink et al., 2002a).  
From these studies, PAX5 fulfils a dual role in B lineage commitment by activating B cell 
specific genes while simultaneously repressing lineage-inappropriate genes (Nutt et al., 
1998). 
More recently, Cobaleda and colleagues (Cobaleda et al., 2007b) showed that conditional 
PAX5 deletion in mice allows mature B cells from peripheral lymphoid organs to de-
differentiate in vivo back to early uncommitted progenitors in the bone marrow, which 
rescues T lymphopoiesis in the thymus of T-cell-deficient mice. These B-cell-derived T 
lymphocytes carry immunoglobulin heavy- and light-chain gene rearrangements but also 
participate as functional T cells in immune reactions. The mice lacking PAX5 in mature B 
cells in the study also developed aggressive lymphomas, which were identified by their 
gene expression profile as progenitor cell tumours. Hence, they concluded that the loss of 
PAX5, in the context of strong BCR signalling results in forward differentiation of mature B 
cells into plasma cells, whereas PAX5 inactivation initiates the reversal of differentiation 
into uncommitted progenitors, in the absence of BCR signalling. 
Thus, in summary, the PAX5 protein is essentially required from pre-B cells to mature B 
cells, as schematically represented in Fig 1. 
2.2.4 PAX5 target genes  
The PAX5 transcription factor represses B lineage-inappropriate genes and activates B-cell 
specific genes in B lymphocytes, functioning both as a transcriptional activator and as a 
repressor on different target genes (Nutt et al., 1998).  
While screening for PAX5-repressed genes, Delogu et al. (Delogu et al., 2006) recently 
estimated that PAX5 represses 44% and activates 56% of the genes, which are differentially 
expressed in PAX5+/+ and PAX5-/- pro-B cells. 
Examples of PAX5-activated genes are co-receptors CD21 (Horcher et al., 2001) and CD19 
(Kozmik et al., 1992), MB-1/CD79a (Maier et al., 2003) and BLNK (Schebesta et al., 2002). 
PAX5-repressed genes are MCSFR (Morrison et al., 1998), NOTCH1 (Souabni et al., 2002) 
and FLT3 (Holmes et al., 2006). Among them, one of the most important targets is CD19, 
which is expressed by B lymphocytes starting from pre-BI cells and lasting to mature B cells 
(Horcher et al., 2001). Its expression is directly controlled by the PAX5 gene; indeed it has 
been demonstrated that a sequence consensus for PD of PAX5 is present in the CD19 
promoter region (Kozmik et al., 1992). 
Delogu and colleagues (Delogu et al., 2006) identified 110 PAX5-repressed genes, 
demonstrating that PAX5 regulates diverse biological activities including receptor 
signalling, cell adhesion, migration, transcriptional control, and cellular metabolism during  
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B-cell commitment. The T lymphoid or myeloid expression of these genes demonstrates that 
PAX5-/- pre-BI cells and common lymphoid progenitors display lymphoid and myeloid 
promiscuity of gene expression. These lineage-inappropriate genes require continuous 
PAX5 activity for their repression because they are reactivated in committed pro-B cells and 
mature B cells following conditional PAX5 deletion (Cobaleda et al., 2007b).  
More recently, Schebesta and colleagues (Schebesta et al., 2007) have identified 170 PAX5-
activated genes, of which 66 (some, already known and some, newly identified) were 
further confirmed to be expressed under PAX5 control. The PAX5-activated genes code for 
key regulatory and structural proteins involved in B cell signalling, adhesion, migration, 
antigen presentation, and germinal-centre B cell formation. Thus they reveal a complex 
regulatory network that is activated by PAX5 to control B-cell development and function. 
Six PAX5-activated genes (CD157, CD44, CD55, CD97, Sdc4, and Tnfrsf19) code for cell-
surface molecules, and nine genes (Bcar3, Capn2, Eps8, Fhod3, Gsn, Myh10, Mylip, Nedd9, and 
Pard3) code for intracellular proteins, which have been implicated in cell migration and 
adhesion. PAX5 has been implicated in the control of pre-BCR signalling by the previously 
characterized PAX5 target genes (CD19, CD79a/Igα, BLNK, etc...) already mentioned above. 
The identification of the PAX5-activated genes Vpreb3, Igk, Slamf6, Siglecg/CD22, Lcp2, 
Plekha2, Prkd2, Ikzf2, and Spib2 has now extended the notion that PAX5 controls signalling 
from the pre-BCR on the cell surface to transcription in the nucleus at multiple levels. 
Comparing T lymphoid and myeloid genes repressed by PAX5 in a specular manner, the 
PAX5-activated genes require continuous PAX5 activity for normal expression in pro-B and 
mature B cells (conditional mutagenesis experiments). Expression of the PAX5-activated 
genes is either absent or significantly reduced upon PAX5 loss in plasma cells. 
In conclusion, target genes that are activated by PAX5 code for essential components of pre-
B- and B-cell receptor (pre-BCR and BCR, respectively) signalling pathways; and when 
PAX5 acts as a transcriptional repressor, its function is to limit lineage choices that differ 
from B cells (Fuxa & Skok, 2007). However, conditional deletion of PAX5 in pro-B and 
mature B cells causes the aberrant reactivation of these repressed targets, thus creating the 
need for continuous repression by PAX5. Surprisingly, even at the transition to the plasma 
cell stage, when PAX5 is physiologically lost during terminal differentiation, repressed 
genes are reactivated and contribute to the plasma cell transcriptional program (Fuxa & 
Skok, 2007). 
3. The PAX5 gene in haematological tumours 
In haematological malignancies, PAX5 was initially described as involved in lymphomas, as 
a target either of mutation in diffuse large B cell lymphomas (DLBCL) (Busslinger et al., 
1996) or of translocation t(9;14)(p13;q32)  in non-Hodgkin’s lymphoma (Lida et al., 1996). 
As recently reviewed (Cobaleda et al., 2007a), in DLBCL, which are germinal-centre B-cell–
derived tumours, exon 1B of PAX5 is the target of misdirected class-switch recombination 
and somatic hypermutations (SHM). SHMs are essential for the affinity maturation of 
immunoglobulins in germinal-centre B cells, but can be potentially misdirected to generate 
oncogenic mutations or chromosomal translocations involved in lymphomagenesis. 
However, the alternatively transcribed exon 1A, as well as the second PAX5 allele, are 
normally expressed; indeed they escape SHMs. The generation of the t(9;14)(p13;q32) 
translocation is due to a misguided class-switch recombination, which is mainly associated 
with aggressive B cell non-Hodgkin’s lymphoma (Souabni et al., 2007). This translocation 
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brings one allele of the PAX5 gene under the control of strong enhancers from the IGH 
locus, leading to its increased expression. The consequence is tumour formation when the 
PAX5-dependent gene expression program alters, due to increased PAX5 transcription in B 
cells or failed PAX5 repression at the onset of plasma cell differentiation. The human t(9;14) 
translocation was recently reconstructed in a knock-in mouse by inserting a PAX5 minigene 
into the mouse’s IgH locus. IgH-PAX5 knock-in mice develop aggressive T-lymphoblastic 
lymphomas, demonstrating that even the T cell lineage is particularly sensitive to the 
oncogenic action of PAX5 (Souabni et al., 2007). 
3.1 PAX5 role in leukaemia  
Abnormalities of the short arm of chromosome 9 (9p) have been described in approximately 
10% of childhood ALL, with a higher incidence in T-ALL (Harrison, 2001). The majority of 
9p abnormalities results in wide-spread (frequently complete) deletion of the chromosome’s 
short arm, which usually includes the cell cycle regulatory genes p14, p15 and p16. More 
specifically, deletions of p16, also known as CDKN2A, have been detected by molecular 
analysis and FISH in approximately 80% of childhood T-ALL and 20% of common-pre-B 
ALL.  
More recently, thanks to technological improvements, a new genetic lesion has been 
identified on 9p, affecting the PAX5 gene in about 30% of BCP-ALL cases (Mullighan et al., 
2007), which can be considered one of the most common alterations. In addition to deletion, 
the PAX5 gene has been reported as a recurrent target of mutation (about 7%) and 
translocation (2-3%), both in adult and in childhood B-Cell Precursor-ALL (BCP-ALL) cases 
with similar incidence (Familiades et al., 2009). 
Both in adult and childhood cases, PAX5 deletions seem to be secondary events, since they 
are frequently associated with other lesions, such as ETV6/AML1 (Mullighan et al., 2007), 
BCR/ABL1 or TCF3/PBX1 (Paulsson et al., 2008; Den Boer et al., 2009; Familiades et al., 
2009; Iacobucci et al., 2010).  
To further confirm the similar PAX5 genetic profile of adult and paediatric BCP-ALL, 
translocations were found in both cohorts, even with the same fusion gene, such as 
PAX5/ELN, PAX5/FOXP1 and PAX5/ETV6, the last, being the most frequent translocation 
compared to the others. Details about the different cohorts and the frequency of partner 
genes are reported in table 1.  
Although the role of these aberrancies is still poorly understood, a different biological 
consequence for mutations/deletions and translocations can be hypothesized.  
3.1.1 Deletions, point mutations and amplifications 
Deletion is the most frequent PAX5 aberrancy, occurring in about 25% of patients. Three 
types of deletions have been found: a) wide-range deletions, involving the full length PAX5 
gene and flanking genes, or even the whole short arm of chromosome 9, extended over 
CDKN2A-2B; b) focal deletions involving a subset of PAX5 exons extending to its 3’ region, 
thus leading to a prematurely truncated gene/protein; c) focal deletions involving only a 
subset of internal PAX5 exons, determining different PAX5 isoforms lacking functional 
domains, such as the DNA binding domain, the octamer or the transcriptional regulatory 
domain. In the larger study in childhood ALL, deletions were monoallelic in 53/192 of the 
cases (27.6%), and among them 25 were focal (13%), while the complete PAX5 was lost in 28 
cases (14.6%); only 3/192  (1.6%) were biallelic (Mullighan et al., 2007). In addition, in the 
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study of adult BCP-ALL, PAX5 is target of exclusively monoallelic deletions in 27/117 cases 
(23.1%) (Familiades et al., 2009). 
Similarly, aberrant splicing variants have been described as alternative mechanisms of 
deletion, both in adults and in children (Santoro et al., 2009). Different isoforms have been 
described, the most frequent lacking either only exon 2, causing frame shift and premature 
stop; or exon 5, corresponding to the octamer domain; or both exons 8 and 9 which encode 
the transactivation domain.  In leukemic blast cells, these variants are more abundant 
compared to full length wild type PAX5, and are predicted to code for less functional or 
even completely non-functional PAX5 proteins. 
Point mutations have been found in about 7% of both adult and paediatric cases. In 
childhood leukaemia cases, point mutations were hemizygous in 14/192 of the cases (7.3%) 
while only 1 case was homozygous (1/192, 0.5%) (Mullighan et al., 2007). A recent study 
reported a higher rate of PAX5 point mutations compared to the previous investigations. 
Point mutations were found in 9/50 (18%) adults and in 14/50 (28%) children, showing 
novel sites of mutations scattered along all the exons (Santoro et al., 2009). Modelling studies 
using the PAX5 crystal structure suggested that point mutation should either impair DNA 
binding, alter transcriptional regulation, or cause frame shift, splice site, or missense 
mutations. A single case with an exon 1B frame shift mutation resulted in a prematurely 
truncated ten-residue peptide.  
Altogether, point mutations are hemizygous, somatically acquired; they result in reduced 
expression of PAX5 mRNA, and lost or altered DNA-binding or transcriptional regulatory 
function (Mullighan et al., 2007; An et al., 2008). Therefore they generate hypomorphic PAX5 
alleles with reduced gene function that could lead to haploinsufficiency. 
An overview of point mutations is represented in Fig. 3. 
 
Exon 1 2 3 4 5 6 7 8 9 10
5’ UTR
DBD OP HD TAD ID
3’ UTR
G18A
V26fs
V26G
P34R
P34Q
R38H
S66N
S67N
I99T
T75A
Y83fs
G149T
P80R
G176L
T194P
E201K
P209S
R239H A279D V319I
A322fs
Q324R
G338W
S353L
G378E
W385G
 
Fig. 3. PAX5 point mutations. DBD, DNA-binding paired domain; OP, conserved 
octapepetide; HD, partial homeodomain; TAD, transactivation domain; ID, inhibitory 
domain. 
Amplifications of the PAX5 gene are less common and include: a) partial amplification, 
which covers a subset of internal exons (in particular from exon 2 to 5/6); b) complete 
amplification, which targets the full sequence of the gene (Mullighan et al., 2007; Familiades 
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et al., 2009). It has been proposed that focal amplification of PAX5 exons 2–5 is predicted to 
abolish expression of normal PAX5 from the amplified allele, although further research is 
required to clarify the importance of this rare genetic lesion. 
Epigenetic mechanisms have been investigated to explain lower PAX5 gene expression, in 
absence of classical rearrangements (e.g. point mutations and deletions) (Mullighan et al., 
2007). However, although high-levels of the PAX5 promoter methylation were detected in T-
ALL, only a minimal methylation level was observed in BCP-ALL, independently by PAX5 
mutational status.  
3.1.2 PAX5 translocations, a new promiscuous gene with several partners 
While the t(9;14) translocation in lymphoma gives rise to PAX5 de-regulated expression, in 
ALL, PAX5 is involved in a growing number of chromosomal translocations with several 
partner genes, resulting in in frame fusion genes, with an estimated frequency of 2-3% in 
paediatric BCP-ALL (Mullighan et al., 2007; Nebral et al., 2009).  
A revision of the literature is reported in Table 1.  
Since the first case encoding for PAX5/ETV6 was identified in 2001 (Cazzaniga et al., 2001), 
as many as 21 known partner genes have been identified in several chromosomes, although 
chromosomes 7, 12 and 20 are the most frequently involved, with different genes on each 
chromosome. Interestingly, PAX5 genetic lesions are typically associated to dicentric 
chromosomes, although the breakpoint on the short arm of chromosome 9 is very 
heterogeneous (An et al., 2008).  PAX5 was rearranged in 54 out of 110 paediatric patients 
carrying a dicentric chromosome: 26/38 of the cases carrying the dic(9;12)(p11~13;p13), 
24/59 positive for the dic(9;20)(p11~13;q11) and in 4/13 of the cases harbouring the 
dic(7;9)(p11;p11~13) (An et al., 2008). Dicentric chromosomes can coexist with established 
chromosomal changes, for example, dic(7;9) is found in association with t(9;22)(q34;q11) 
(BCR/ABL1 fusion), and dic(9;12) occurs with t(12;21)(p13;q22) (ETV6/RUNX1 fusion), 
suggesting that these events may cooperate. 
A more recent study confirmed the involvement of the PAX5 gene in dicentric chromosome 
events in adult and childhood BCP-ALL (Coyaud et al., 2010a). In this study, 40 patients (14 
adult and 26 paediatric) harboured a dicentric chromosome involving chromosome 9 with 
various different partners (such as, 7, 8, 12, 15, 16, 17, 20) and as much as 90% of the cases 
involved PAX5 alterations.  
The various fusion genes can be classified in different sub-groups according to the 
molecular function of the PAX5 partner gene, which can encode either for a transcription 
factor (e.g. ETV6/TEL, PML, FOXP1, ZNF521/EVI3, BRD1, DACH1), for proteins related to 
transcription regulation (HIPK1, NCOR1), structural proteins (ELN, POM121, LOC39027, 
KIF3B), kinases (JAK2, TAOK1), carriers of molecules (SLCO1B3) or co-activator proteins 
(ASXL1). The implicated genes encode less frequently for molecules of unknown function 
(e.g. C20orf112, AUTS2, GOLGA6). Among this plethora of fusion genes, PAX5/ETV6 
originating from the translocation t(9;12) or dic(9;12) is the most common.  
A common feature of PAX5 translocations is that they result in the fusion of the 5’ N-
terminal DNA-binding domain of PAX5 (PAX5-DBD) with the 3’ C-terminal sequences of 
the partner gene, whose domains therefore substitute PAX5 regulatory domains. The 
breakpoints are mostly located after exon 5 of PAX5, or after exon 4, at the end of the DBD 
region. Cases with a more distal PAX5 breakpoint are less common and retain additional 
domains, including the highly conserved Octamer domain.  
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°=paediatric patient (<16 years old) ; #=adolescent patient (16-18 years old); *=adult patient (>18  
years old)  
Table 1. Reported PAX5 translocations and corresponding fusion genes. 
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As a further feature, PAX5 translocations are unbalanced (An et al., 2008), and therefore the 
reciprocal fusion gene (5’ partner gene to 3’ PAX5) is not preserved, with the sole known 
exception of the translocation, t(9;9)(p13;p24), encoding for PAX5/JAK2 (Nebral et al., 2009).   
ETV6/TEL, ELN and FOXP1 are recurrent partner genes, independent of patient age, as well 
as translocation events giving rise to PAX5-truncated isoforms.  
Although the biological significance of PAX5 translocations has not been elucidated yet, it 
has been demonstrated that patients with dicentric chromosomes carrying either a deletion 
or a fusion significantly under-expressed the PAX5 gene, thus indicating that both genetic 
alterations can result in a similar reduced expression of wild-type PAX5 (An et al., 2008). 
These data would suggest that PAX5 haploinsufficiency has a major consequence in 
patients. However, this is not supported by the in vivo studies, B-cell development being 
normal in heterozygous PAX5+/– mice (Cobaleda et al., 2007b). Moreover, inactivation of one 
PAX5 allele in the absence of other oncogenic lesions is not sufficient to induce tumour 
development in heterozygous Cd19-cre Pax5fl/- mice. Instead, the complete loss of PAX5 in 
B cells leads to an aggressive progenitor cell lymphoma, thus identifying PAX5 as a tumour 
suppressor gene of the different B-lymphoid lineage malignancies (Cobaleda et al., 2007b).  
Furthermore, even though in some cases the translocation events lead only to a truncated 
form of PAX5, it can be speculated that the role of PAX5 in this setting can be different from 
deletions or point mutations. The fusion protein could retain the functional activities of the 
partner genes and therefore it may alter the molecular function of the normal counterparts, 
affecting both the partner gene and wild type PAX5 functions. Indeed, many of the PAX5 
fusion genes have a dominant negative role on normal PAX5; in fact, in leukemic blasts, 
expression analysis revealed that its transcriptional targets (e.g. EBF1, FLT3, ATP9A, 
ALDH1A1) are repressed in dicentric cases, indicating a reduced activity of wild type PAX5 
(An et al., 2008). Despite these data, CD19 and CD79a expression (direct PAX5 targets) did 
not correlate with PAX5 altered status (Mullighan et al., 2007).   
Comprehensively, several fundamental questions on PAX5 involvement in leukemogenesis 
are still unresolved. Two points remain to be understood: 1) whether these genetic 
alterations are responsible for the disruption of PAX5 functions, generating a 
haploinsufficiency setting;  2) whether these lesions are more generally responsible for the 
B-cell development block, through deregulation of PAX5 control, which is crucial for normal 
B lymphopoiesis. A more important role for fusion genes cannot be excluded, in which a 
gain of function could lead to cell transformation. In vitro and in vivo studies will be helpful 
to better elucidate the role of fusion genes. 
The molecular and functional role of most relevant fusion genes will be addressed in 
paragraph 4.   
4. Molecular and functional analysis of PAX5 fusion genes 
Although a huge amount of work has to be done to characterize the functional role of the 
PAX5 fusion proteins, we have revised the functional studies reported in literature to 
discuss the most corroborated hypothesis, that these fusion proteins could act as aberrant 
transcription factors, deregulating the physiological pathway of wild type PAX5, and 
potentially the normal function of the partner gene as well.  
Since the availability of patient material is always a limiting factor, human and mouse 
biological in vitro models have been developed to make the functional investigations of 
PAX5 fusion proteins possible. Among the different models, a common strategy has been 
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employed to transiently or stably transfect cells by a plasmid that contains the sequence of a 
variously tagged fusion gene cloned from a patient. 
Here, we focus on studies regarding PAX5/ETV6, PAX5/FOXP1, PAX5/PML, PAX5/ELN and 
PAX5/C20orf112 fusion genes, all of which are in frame genes and are predicted to be 
translated into protein.  These partner genes are representative of different functional 
classes, being transcription factors (ETV6, FOXP1, PML), structural proteins (ELN) or 
unknowns (C20orf112). 
The ETV6 (or TEL) gene encodes for a transcription factor with suppressor function, 
belonging to the highly conserved ETS family, which is fundamental for the haematopoietic 
system. It is widely acknowledged that it is involved in several translocations giving rise to 
different fusion genes in various haematological malignancies. Among them, ETV6/AML1 
is the most recurrent in childhood BCP-ALL (Bohlander, 2005).  
Forkhead Box P1 (FOXP1) is a member of the FOX family of evolutionarily conserved 
transcriptional regulators, which have a broad range of functions. FOXP1 is widely 
expressed and has been shown to have a role in cardiac, lung and lymphocyte development, 
In mice, FOXP1 deficiency is associated with a block in transition from pro-B cells to mature 
B cells. FOXP1 is targeted by recurrent chromosome translocations and its over-expression 
confers a poor prognosis in a number of types of lymphomas, suggesting that it may 
function as an oncogene (Koon et al., 2007; Myatt & Lam, 2007).  
The Promyelocytic leukaemia gene (PML) encodes for a protein which is a member of the 
tripartite motif (TRIM) family. The TRIM motif includes three zinc-binding domains, a 
RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. This phosphoprotein 
functions as a transcription factor and tumour suppressor. The gene is often involved in 
translocation with the Retinoic Acid Receptor alpha (RARα) gene associated with acute 
promyelocytic leukaemia (APL), a relatively rare form of acute myelogenous leukaemia 
(AML) (Gregory & Feusner, 2009). 
The ELN gene encodes for the protein elastin, an extracellular matrix macromolecule that 
imparts arterial elasticity and plays a critical role in maintaining vessel integrity and elastic 
properties under pulsatile flow. Elastin plays an important role in signalling and regulating 
luminal endothelial cells and smooth muscle cells in the arterial wall (Waterhouse et al., 
2011). 
The function of C20orf112 is totally unknown; it is described as involved in translocation 
events, with the RUNX1 gene in AML (Guastadisegni et al., 2010) and with the PAX5 gene 
in ALL. Kawamata et al. identified two different rearrangements of PAX5/C20orf112, which 
were defined as long or short respectively, since in one case with dic(9;20), exon 5 of PAX5 
was fused to exon 8 of C20orf112 (PAX5/C20L), and in the other case, with dic(9;20), exon 8 
of PAX5 was fused to exon 3 of C20orf112 (PAX5/C20S) (Kawamata et al., 2008). 
4.1 Sub-cellular localization, DNA binding ability and transcription activity of PAX5 
fusion genes 
PAX5 encodes for a transcription factor, which by definition localizes in the nucleus and 
regulates several target genes through the binding of a specific consensus sequence on DNA 
(Delogu et al., 2006; Schebesta et al., 2007). Therefore, the first issues to be addressed are 
where PAX5 fusion proteins localize in the cell and whether they conserve the ability to bind 
DNA, with an effect on the transcription process.  
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By confocal analysis in transfected NIH3T3, PAX5/ELN has been demonstrated to localize 
exclusively in the nucleus (Bousquet et al., 2007), as we showed for PAX5/ETV6 (Fazio et al., 
2008). While PAX5/ELN retains the nuclear localization signal (NLS) of wt-PAX5, this 
domain is not retained in the PAX/ETV6 fusion protein, but its activity could be exerted by 
the corresponding ETV6 NLS. By sub-cellular fractionation and western blot analysis in 
transfected 293T cells, it has been shown that PAX5/ETV6, PAX5/FOXP1 and PAX5/C20S 
were present mainly in the nucleus and less abundant in the cytoplasm, while PAX5/C20L 
was exclusively nuclear (Kawamata et al., 2008). In agreement with these data, fluorescent 
microscopic examination of transiently expressed proteins in HeLa and 293T cells 
demonstrated that PAX5/PML exhibited a diffuse granular pattern within the nucleus, 
similar to PAX5 but not to PML (Qiu et al., 2011).  
To support the aberrant transcription factor activity, the DNA binding activity of PAX5 
fusion genes has been assessed by a direct (through electrophoretic mobility shift assay, 
EMSA) or indirect (such as the luciferase reporter assay) binding measure. Kawamata 
demonstrated the specific binding for PAX5/ETV6, PAX5/FOXP1 and PAX5/C20orf112 in 
parallel to wild type PAX5 (Kawamata et al., 2008). In an analogous setting, it has been 
demonstrated that PAX5/PML is able to bind to PAX5-responsive elements (Qiu et al., 
2011).  A formal demonstration of DNA binding by PAX5/ELN is missing in literature, 
although the transcriptional activity of PAX5 fusion genes, including the PAX5/ELN, has 
been proven by reporter gene assays (Bousquet et al., 2007; Mullighan et al., 2007; 
Kawamata et al., 2008; Kurahashi et al., 2011; Qiu et al., 2011). 
4.2 Fusion genes have a dominant effect on wild type PAX5 
The PAX5 fusion proteins herewith described retained the DNA-binding domain of PAX5 
but substituted its regulatory domains with those of the partner gene, which are mostly 
responsible for transcription regulation.  
PAX5/ETV6 fusion merits a special focus for the central role of the ETV6/TEL partner gene in 
onco-haematology, and because PAX5/ETV6 is the most common PAX5 translocation. 
We previously showed that PAX5/ETV6 maintains the transcriptional activity common to 
both partner genes and it is responsible for the down-regulation of key PAX5-targets, such as 
CD19, BLNK/SLP-65 and MB-1/CD79a through recruitment of the mSIN3a co-repressor (Fazio 
et al., 2008). We investigated PAX5/ETV6 function through gene expression profile (GEP) 
analysis by stable transduction of the PAX5/ETV6 construct in wild type (wt) pre-BI cells, a 
primary culture of immature B-cells (cKit+/B220+/CD19+) from mouse fetal liver, which 
express the endogenous wild type PAX5 protein (Fazio et al., 2008). GEP analysis defined a 
PAX5/ETV6 specific signature, indicating that PAX5/ETV6 acts mainly as a repressor of 
transcription but, surprisingly, the fusion protein was also able to activate transcription. 
Among DEGs we identified a reliable number of genes (7%) known to be direct transcriptional 
targets of PAX5 (Delogu et al., 2006; Schebesta et al., 2007). These results strongly suggest that 
PAX5/ETV6 primarily affects the PAX5 transcriptional pathway by repressing PAX5-target 
genes normally activated by wt PAX5 and by up-regulating genes known to be PAX5 wt-
repressed. This supports a dual function for PAX5/ETV6 on transcription, which is mainly a 
repressor but also to a lesser extent, an activator. Therefore, PAX5/ETV6 does not exert a 
canonical “dominant negative” effect on the endogenous protein whilst it does have an “opposite 
dominant” function on wt PAX5 (Fazio et al., 2010).  
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A canonical dominant negative effect of fusion over wt PAX5 was demonstrated for 
PAX5/ELN, PAX5/FOXP1, PAX5/PML and PAX5/C20orf112. As in the context of 
PAX5/ETV6, various PAX5 transcriptional targets are repressed by PAX5 fusion proteins, 
such as CD19, MB-1/CD79a, BLNK, NEDD9, NEDD5, ATP1B1, TCF7L2, resulting in reduced 
PAX5 wild type activity. 
Certainly, the molecular mechanism through which repression is achieved includes the 
competition for binding the consensus sequence on DNA between wt PAX5 and its fusion 
protein. A novel insight has been provided by the study on PAX5/PML (Qiu et al., 2011), in 
which they showed that PAX5/PML forms homodimer to bind the PAX5 consensus sequence 
through the Coiled-Coiled (CC) domain of PML. Furthermore, PAX5/PML can form 
complexes with PAX5/PML as well as wild-type PML. The intranuclear mobility of 
PAX5/PML is decreased compared with wild-type PAX5, in analogy to other fusion proteins 
in leukaemia, such as PML/RAR┙ and AML1/ETO (Dong & Blobe, 2006; Qiu et al., 2011).  
Since other PAX5 fusion proteins from ALL patients such as PAX5/FOXP1 and PAX5/EVT6 
maintain the dimerization motif of the PAX5 partner, the aberrant molecular mechanism 
proposed for PAX5/PML can be valid for other PAX5 fusion genes as well. 
4.3 Functional consequences of PAX5 fusion genes on cellular processes in 
precursor B cells  
Preliminary results indicate that the wt PAX5 protein is present at lower levels in cells 
positive for translocation (An et al., 2008). In patients with PAX5 translocation, we see that 
one PAX5 allele is involved in the translocation event, while the second allele could be 
partially repressed and also hindered by the fusion protein in its function, by competition 
and by dynamic deregulation of target genes. Moreover, PAX5 mutations result in reduced 
levels of PAX5 protein and corresponding activity (Mullighan et al., 2007).  
In the B-cell context, the biological consequences of decreased normal PAX5 function plus 
the opposite dominance of the fusion protein could be various.  
A pathway analysis of GEP results revealed the involvement of several cellular processes, 
specifically: B-Cell Receptor assembly and B-cell maturation, cell adhesion and migration 
(our unpublished observations). PAX5/ETV6 cells are impaired to complete the IgM 
rearrangement, and consequently the precursor B cells are immature and unable to complete 
the differentiation process (Mullighan et al., 2007; Fazio et al., 2008). This could be due to the 
direct down-regulation of pre-BCR components, such as the µ chain itself, Ig┙/MB-1, and 
BLNK/SLP-65. This incapacity to express a pre-BCR on the cell surface has already been 
demonstrated in primary leukemic ALL blast cells, in the presence of the BCR/ABL1 fusion 
gene (Trageser et al., 2009). It is possible to speculate that the survival of precursor B cells 
carrying a PAX5 fusion gene could be guaranteed by alternative signalling pathways. 
Overall, these data suggest that PAX5 behaves like a tumour suppressor in early B cells, and 
that impairment of its function can be associated with the development of ALL (Kawamata 
et al., 2008). 
4.4 Future perspective of functional studies 
Preliminary results indicate that PAX5/ETV6 cells have a significant advantage over in vitro 
migration to CXCL12 (Fazio et al., 2008). In humans, cells with aberrant PAX5 could 
therefore have a greater ability  to aggressively infiltrate CXCL12-secreting tissues and 
organs, and thus proliferate and survive better, as described in several tumours (Burger & 
Burkle, 2007).  
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In the near future, the in vivo mouse models will be crucial for studying the role of 
translocation on leukemogenesis. Currently, the xenotransplantation of human primary 
patient cells into immune-deficient mice is the ‘gold standard’ assay to identify human 
leukemic stem cells and functionally assess their tumorigenicity in vivo. The availability of 
primary samples from patients carrying a PAX5 fusion gene will shed light on the human 
setting. 
Among the main questions in leukaemia research is how and in what temporal sequence the 
genetic lesions lead to abnormal proliferation and differentiation arrest of lymphoid 
progenitors.  
Beside a dissection of the role of PAX5 translocations in leukaemia, several additional 
questions on PAX5 aberrancies in ALL are still unresolved, namely: 
- Are PAX5 translocations responsible for blocking B-cell development?  
- Are PAX5 translocations per se sufficient in leukemogenesis?  
5. Are PAX5 alterations driver or passenger lesions?  
Studies on ALL patients and/or in vitro models concentrated the efforts to understand 
whether PAX5 alterations are part of a complex scenario of cooperating genetic lesions or 
whether they are a unique genetic aberration event that drives leukemogenesis.  
Patients carrying PAX5 deletion have a more complex karyotype than patients with 
translocation or dicentric chromosomes. Frequently, classical deletion events or dicentric 
chromosomes giving rise to prematurely truncated PAX5 transcripts have been described as 
co-existing in leukemic blast cells together with other PAX5-unrelated genetic lesions, such 
as ETV6/AML1 (Mullighan et al., 2007), BCR/ABL1 and TCF3/PBX1 fusion genes (Paulsson et 
al., 2008; Den Boer et al., 2009; Familiades et al., 2009; Iacobucci et al., 2010). This observation 
led us to hypothesize that there is a cooperative role for PAX5 deletions over the main 
genetic lesion. Similarly to micro-deletions on fundamental genes in haematopoiesis (such 
as IKZF1, EBF1, TCF3, LEF1) (Mullighan et al., 2007; Paulsson et al., 2008), PAX5 aberrancies 
can contribute to blocking cell development in B cell precursors, as reflected in the mouse 
model of homozygous PAX5 deletion, which is characterized by complete blockage at an 
early stage of differentiation (Nutt et al., 1999).  
By contrast, patients with PAX5 fusion genes (as a consequence of translocations) were 
mainly reported as negative for the most common genetic aberrations found in childhood 
(Nebral et al., 2009; Coyaud et al., 2010a).   
A high resolution Copy Number Abnormality (CNA) analysis on diagnostic samples with 
PAX5 fusion genes revealed that in both childhood and adult ALL, PAX5-translocated cases 
have a simple karyotype (Coyaud et al., 2010a), with a mean of only three lesions in addition 
to the translocation event itself (our unpublished observation).  
In conclusion, it becomes evident that PAX5 translocations giving rise to fusion genes have a 
completely different impact on the biology and development of leukaemia compared to 
PAX5 deletions. It can be argued that gene fusions occur early, whereas deletions can be 
regarded as a late/secondary event (Coyaud et al., 2010a). We can therefore presume that 
PAX5 fusion genes are driver genetic lesions, whereas PAX5 deletions can be a cooperative 
aberrancy, which require further alteration to determine the disease.  
The final word on the real impact of PAX5 alterations will come in the near future from 
robust functional studies, including the development of an appropriate in vivo 
leukemogenesis model. 
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6. Are PAX5 alterations associated to prognosis and/or outcome? Is PAX5 a 
new target for leukaemia treatment? 
Although the frequency and the molecular nature of PAX5 aberrancies are analogous, the 
complexity and biological differences between adult and childhood B-ALL may reflect 
another example of the importance of PAX5 alterations on the disease course.  
Gene expression profiling (GEP) of childhood ALL has identified a genetic subtype of 
childhood ALL with a poor outcome, that clusters close to the subgroup characterized by 
the BCR/ABL fusion gene (thus called ‘BCR/ABL like’). Patients in this group carry mutations 
in genes that are fundamental in B-cell development, such as IKZF1, PAX5, VPREB1, TCF3, 
EBF1 and pre-BCR (Den Boer et al., 2009; Mullighan et al., 2009).  
A study by Mullighan et al. showed that PAX5 abnormalities were not associated with an 
unfavourable prognosis, in contrast to the BCR/ABL-like subtype (Mullighan et al., 2007). 
Deletions in the BCR/ABL-like group not only affect the PAX5 gene locus but often include 
larger regions on chromosome 9p and other genes involved in B-cell development. This 
suggests that the BCR/ABL-like group does not exactly overlap with the subgroup of BCP-
ALL patients carrying exclusively PAX5 abnormalities. 
A genome-wide DNA copy number analysis on matched diagnosis and relapse samples 
from paediatric patients with ALL detected an increasing number of additional regions of 
deletion at relapse, including the PAX5 and IKZF1 genes. This suggests that genomic 
abnormalities contributing to ALL relapse, including PAX5 alterations, are selected during 
treatment, paving the way for designing a new therapeutic intervention to target these 
abnormalities (Mullighan et al., 2008). 
Even in adult ALL, PAX5 alterations are not associated to outcome (Familiades et al., 2009), 
except for a reported trend toward a higher incidence of relapse in the structural mutant 
PAX5 subgroup.  
Indeed, deletions of PAX5 were not significantly correlated with overall survival, disease-
free survival or cumulative incidence of relapse in BCR/ABL1-positive ALL adult cases 
treated with conventional or investigational therapy including TKI (imatinib or dasatinib) 
(Iacobucci et al., 2010).  
In conclusion, the state of the art on PAX5 alterations and prognosis gives evidence that no 
significant correlation exists in paediatric or in adult BCP-ALL. Nevertheless, considering 
the biology of the different subgroups of genetic lesions (point mutations vs. deletions vs. 
translocations), we cannot completely exclude the possibility that the sole translocation 
event may have a different significance and influence on the clinical course of the disease, 
although the limited number of cases in the reported studies hamper a statistically 
significant analysis.  
We need further clinical data to show whether PAX5 could be a new target for leukaemia 
treatment, and to inspire the design of a strategy to target the molecule itself or to interfere 
with its aberrant activity.  
7. Conclusion 
The PAX5 gene, encoding for a transcription factor fundamental for B-cell development, is 
the most recurrent target of genetic lesions in BCP-ALL disease, both in the adult and 
paediatric population. Its alterations are a hallmark which defines a new molecular 
subgroup of patients.  
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Although in general, PAX5 translocations do not influence the prognosis or outcome by 
themselves but in association to other molecular aberrancies, we can hypothesize that they 
could play a different role from deletions and point mutations. 
Further clinical investigations are needed to assess the real impact of PAX5 alterations on 
disease progress. In parallel, we believe that in vitro and in vivo models will help to clarify 
the biological basis of leukemogenesis driven by PAX5, especially in presence of its fusion 
genes.  
If we are able to fill these biological and clinical gaps, we could recognize the altered PAX5 
molecule as a novel target to hit, with the final purpose of eradicating leukaemia.  
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